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A potential mode of action 
for Anakinra in patients with 
arthrofibrosis following total knee 
arthroplasty
David Dixon1, Jonathon Coates1, Alicia del Carpio Pons1, Joanna Horabin1, Andrew Walker1, 
Nicole Abdul1,2, Nicholas S. Kalson1,2, Nigel T. Brewster2, David J. Weir2, David J. Deehan1,2, 
Derek A. Mann1 & Lee A. Borthwick1
Arthrofibrosis is a fibroproliferative disease characterised by excessive deposition of extracellular 
matrix components intra-articularly leading to pain and restricted range of movement. Although 
frequently observed following total knee arthroplasty (TKA) no therapeutic options exist. A pilot 
study demonstrated that intra-articular injection of Anakinra, an IL-1R antagonist, improved range 
of movement and pain in patients with arthrofibrosis however the mechanism of action is unknown. 
We hypothesise that IL-1α/β will drive an inflammatory phenotype in fibroblasts isolated from the 
knee, therefore identifying a potential mechanism of action for Anakinra in arthrofibrosis following 
TKA. Fibroblasts isolated from synovial membranes and infra-patellar fat pad of patients undergoing 
TKA express high levels of IL-1R1. Stimulation with IL-1α/β induced a pro-inflammatory phenotype 
characterised by increased secretion of GMCSF, IL-6 and IL-8. No significant difference in the 
inflammatory response was observed between fibroblasts isolated from synovial membrane or infra-
patellar fat pad. IL-1α/β treatments induced a pro-inflammatory phenotype in fibroblasts from both 
synovial membrane and infra-patellar fat pad and therefore Anakinra can likely have an inhibitory 
effect on fibroblasts present in both tissues in vivo. It is also likely that fibroblast responses in the 
tissues are controlled by IL-1α/β availability and not their ability to respond to it.
Total knee arthroplasty (TKA) is one of the most successful orthopaedic procedures that substantially 
reduces pain associated with degenerative knee joint diseases. There were 153,133 primary knee arthro-
plasties performed in 396 centres throughout England and Wales in a 2-year period and over 1.5 million 
are performed worldwide each year1. The surgery involves the resection of diseased or damaged bone 
from intra-articular areas of the knee followed by implantation of metal and polyethylene prosthetic 
replacements2. Although a very high success rate is observed with TKA surgery some 3-10% of individ-
uals go on develop fibrosis in the form of arthrofibrosis post-surgery3–5.
Arthrofibrosis following TKA is characterised by the excessive deposition of extracellular matrix 
components (ECM) intra-articularly resulting in the formation of dense fibrous tissue and tissue meta-
plasia. This abnormal scarring of the joint prevents normal range of motion, represents a significant 
clinical challenge and drastically reduces quality of life of those affected individuals4. Currently there 
are no prophylactic intervention available and treatment for arthrofibrosis is restricted to aggressive 
physiotherapy or revision surgery6,7. However a pilot clinical study by Brown et al. demonstrated that 
intra-articular injection of Anakinra, an interleukin-1 receptor (IL-1R) antagonist, into patients who 
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developed arthrofibrosis following TKA improvement range of motion and pain with 75% of patients 
able to return to prior activity levels8. This study is the first to identify a beneficial effect for inhibiting 
IL-1R1 in patients with arthrofibrosis however the mechanism of action of Anakinra in the knee is 
unknown.
Fibroblasts and myo-fibroblasts are cells of distinct morphology and are the most abundant cell found 
in connective tissue. During physiological wound healing the fibroblast plays a critical role in the restora-
tion of tissue architecture and function however they have also been identified as one of the major effec-
tor cells involved in pathological wound repair and the development of fibrosis in multiple organs9–11. 
The role of the fibroblast as the major fibrogenic cell is well characterised, however less is known about 
the potential for these cells to contribute to inflammatory responses. Recently published work from our 
laboratory has shown that human lung fibroblasts express high levels of IL-1R1 and are induced to adopt 
a highly inflammatory phenotype in response to ligation of IL-1R1. Furthermore, mice lacking IL-1R1 
are protected from bleomycin induced lung fibrosis12 further highlighting the importance of IL-1R1 in 
the development of fibrosis.
Unterhauser et al. have reported a 10 fold increase in the frequency of α -SMA containing contractile 
fibroblastic cells in knee arthrofibrotic tissue after anterior crucial ligament reconstruction13 suggesting 
a potentially important role for these cells in the pathophysiology of arthrofibrosis. In this study we 
demonstrate that fibroblasts isolated from the infrapatellar fat pad and synovial membrane express high 
levels of IL-1R1 on their cell surface and adopt a highly inflammatory phenotype in response to stimu-
lation with IL-1α or IL-1β . We hypothesise the blockade of IL-1R1 on fibroblasts as a potential mode of 
action for Anakinra in patients with arthrofibrosis.
Results
Phenotyping of cells isolated from the infra-patellar fat pad and synovial membrane. Cells 
were isolated from the infra-patellar fat pad and synovial membrane of patients undergoing primary 
TKA as described in the materials and methods. Cell phenotype was determined by assessing the expres-
sion of endothelial, epithelial and mesenchymal markers using immunocytochemistry and Western blot-
ting. Primary human lung epithelial cells were stained as a positive control for epithelial markers. Cells 
from the infra-patellar fat pad (Fig. 1a, supplementary Figure 1) and synovial membrane (Supplementary 
Figure 2a, c) have little to no expression of the epithelial markers cytokeratin 17, E-cadherin and ZO-1 
or the endothelial markers CD31 (data not shown). Inserts show positive staining for epithelial markers 
in human lung epithelial cells. The lack of expression of an epithelial marker, E-cadherin, was confirmed 
by Western blotting (Fig. 1b, Supplementary Figure 2b). β -tubulin staining visibly demonstrates the bipo-
lar morphology of the cells, a typical characteristic of mesenchymal cells. In addition, high levels of 
Figure 1. Cells isolated from the infra-patellar fat pad demonstrate a mesenchymal phenotype.  
(a) Cells isolated from the infra-patellar fat pad were cultured in vitro and the expression of epithelial 
and mesenchymal markers investigated by immunocytochemistry. Cells had little to no expression of 
the epithelial markers cytokeratin 17, E-cadherin and ZO-1. Insets show positive staining on human 
lung epithelial cells. β -tubulin was used to demonstrate cell morphology. In contrast cells expressed very 
high levels of the mesenchymal markers vimentin, collagen 1, α -SMA and fibronectin. DAPI was used 
as a nuclear counter stain. Images were acquired on a Leica TCS SP2 UV confocal microscope at x20 
magnification. (b) Whole cell lysates of infra-patellar fat pad derived fibroblasts (n = 5) were investigated 
for the expression of epithelial and mesenchymal markers by Western blotting. Cells express high levels 
of fibronectin and vimentin but no E-cadherin. β -actin was used as a loading control. Human bronchial 
epithelial cells (16HBE14o- (HBE)) were used as a positive control for epithelial marker expression.
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expression of the mesenchymal makers vimentin, collagen 1, α -SMA and fibronectin were observed in 
cells isolated from the infra-patellar fat pad and synovial membrane. Yellow regions indicate overlapping 
of positive mesenchymal signals. The expression of mesenchymal markers, fibronectin and vimentin, was 
confirmed in n = 5 sets of patient cells by Western blotting (Fig.  1b, Supplementary Figure 2b). These 
data confirm that the cells isolated from the infra-patellar fat pad and synovial membrane represent a 
uniform population of fibroblasts/mesenchymal cells.
TGF-β 1 is widely accepted as a key mediator of fibrosis in multiple organs and has been demon-
strated to be elevated in arthrofibrotic tissue14. Treatment of infra-patellar fat pad (Fig. 2) and synovial 
membrane (supplementary Figure 3) derived fibroblasts with TGF-β 1 increased expression of α -SMA, a 
marker of fibroblast activation, as well as collagen I, collagen III and fibronectin, key extra cellular matrix 
proteins involved in fibrosis.
Determining receptor expression on fibroblasts. Previous work in the laboratory has identified 
that fibroblasts isolated from human lung tissue express a range of TLR’s and PRR’s that are distinct from 
immune cells12. Therefore we proceeded to investigate the expression of TLR’s (1–10) and PRR’s (IL-
1R1, RAGE, RIG-1) on fibroblasts isolated from the infra-patellar fat pad and synovial membrane using 
qRT-PCR (Fig.  3a,b). Fibroblasts from both the infra-patellar fat pad and synovial membrane (n = 5) 
strongly expressed TLR 3 and TLR4 whereas all other TLRs were negligible or undetectable. The level of 
expression of TLR 3 and TLR4 was comparable between cells isolated from the infra-patellar fat pad and 
synovial membrane. IL-1R1 was expressed at very high levels, ~100 fold greater than TLR 3 and TLR4 in 
cells isolated from the infra-patellar fat pad and ~150 fold greater than TLR 3 and TLR4 in cells isolated 
Figure 2. TGF-β1 treatment of infra-patellar fat pad derived fibroblasts upregulates fibrotic gene 
expression. Fibroblasts isolated from the infra-patellar fat pad (n = 6) were cultured in vitro in the presence 
or absence of TGF-β 1 (3 ng/ml) for 48 hours and the relative gene expression of (a) α -smooth muscle actin 
(α -SMA), (b) collagen I, (c) collagen III and (d) fibronectin quantified by qRT-PCR. The expression of 
all fibrotic genes was increased by TGF-β 1. Data is presented as mean ± standard error of the mean with 
statistical significance indicated by; *p < 0.05 and **p < 0.01.
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Figure 3. Interleukin-1 receptor 1 is highly expressed on infra-patellar pad derived fibroblasts. 
Fibroblasts isolated from the infra-patellar fat pad and synovial membrane (both n = 5) were cultured in 
vitro and the relative gene expression of TLR1-10, RIG-1, RAGE and IL-1R1 quantified by qRT-PCR.  
(a) TLR expression was restricted mainly to TLR3 and TLR4 with little or no expression of other TLRs.  
(b) There was no detectable expression of RAGE but RIG-1 was expressed at levels comparable to TLR3 and 
TLR4. In contrast IL-1R1 expression was 100–150 fold greater than other receptors. Results are normalised 
to GAPDH as a loading control. Data is presented as mean ± standard error of the mean. Fibroblasts isolated 
from the infra-patellar fat pad were investigated for the expression of TLR3, TLR4 and IL-1R1 protein by 
Western Blotting (n = 4) (c) and flow cytometry (n = 6) (d). Cells expressed TLR3 and TLR4 at comparable 
levels at the cell surface. In contrast, expression of IL-1R1 was significantly higher than other receptors (red 
traces). β -actin was used as a loading control (c). Unstained cells (filled traces) and IgG controls (black 
traces) were used as flow cytometry controls (d).
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from the synovial membrane. In contrast, RAGE was absent in both sets of fibroblasts and RIG-1 was 
present at levels comparable to TLR3 and TLR4.
We proceeded to investigate the expression of TLR3, TLR4 and IL-1R1 at a protein level using 
Western blotting and to investigate if these receptors are present on the cell surface using flow cytome-
try. The expression of TLR3, TLR4 and IL-1R1 at a protein level was confirmed in n = 4 sets of patient 
cells by Western blotting (Fig. 3c, Supplementary Figure 4a). Furthermore, flow cytometry demonstrated 
that fibroblasts from both the infra-patellar fat pad and synovial membrane (n = 6) strongly expressed 
IL-1R1 at the cell surface with a more limited expression of TLR3 and TLR 4 at the cell surface (Fig. 3d, 
Supplementary Figure 4b–d).
These data confirm that fibroblasts isolated from the infra-patellar fat pad and synovial membrane 
express IL-1R1 (+ + + ), TLR3 (+ ) and TLR4 (+ ) on their cell surface.
Stimulation of fibroblasts from the infra-patellar fat pad and synovial membrane. Fibroblasts 
isolated from infra-patellar fat pad and synovial membrane (n = 6) were stimulated for 24 hours with 
increasing doses of receptor ligands (LPS—TLR4, HMGB1—RAGE, PolyIC—TLR3, IL-1α & IL-1β —
both IL-1R1) and the secretion of pro-inflammatory cytokines (IL-6, IL-8, and GM-CSF) investigated. 
Treatment of fibroblasts from both the infra-patellar fat pad and synovial membrane with LPS at the 
lowest dose tested in this study (0.1 mg/ml) maximized secretion of IL-6, IL-8 and GM-CSF, with higher 
doses (up to 20 ng/ml) exhibiting a reduced response. As expected given the lack of RAGE expression in 
these cells, HMGB-1 up to concentrations of 200 ng/ml had little to no effect on the secretion of IL-6, 
IL-8 and GM-CSF in fibroblasts from either the infra-patellar fat pad or the synovial membrane. In con-
trast, treatment with PolyIC induced a dose dependant increase of IL-6, IL-8 and GM-CSF secretion in 
fibroblasts isolated from both tissues. The magnitude of the GM-CSF response to PolyIC was similar to 
that induced by LPS but PolyIC induced significantly higher levels (~2–3 fold) of IL-6 and IL-8. Finally, 
treatment with IL-1α and IL-1β induced a dose dependant increase in the secretion of IL-6, IL-8 and 
GMCSF in fibroblasts isolated from both tissues. The magnitude of the response to IL-1α and IL-1β 
was significantly higher for IL-6, IL-8 and GMCSF compared to PolyIC and LPS (Fig. 4, Supplementary 
Figure 5). No secretion of TNFα from fibroblasts isolated from the infra-patellar fat pad or synovial 
membrane was detected in response to any of the treatment (data not shown).
Given the varied inflammatory response induced by single ligand stimulation, we proceeded to deter-
mine if co-stimulation with ligands would produce additive, synergistic or inhibitive responses. To do 
this we stimulated synovial membrane and infra-patellar fat pad derived fibroblasts (n = 6) with IL-1α 
(500 pg/ml), IL-1β (500 pg/ml), LPS (5 μ g/ml), PolyIC (5 μ g/ml) or HMGB-1 (50 ng/ml) alone or in com-
bination for 24 hours and measured secreted levels of IL-8, IL-6 and GM-CSF by ELISA. As we previ-
ously demonstrated, IL-1α and IL-1β treatment induced the secretion of GMCSF, IL-6 and IL-8 from 
fibroblasts isolated from the infra-patellar fat pad and synovial membrane. Co-stimulation with IL-1α 
or IL-1β and PolyIC induced a synergistic response to greatly increase GMCSF secretion. In contrast 
an additive effect on IL-6 and IL-8 secretion was observed by co-stimulating with IL-1α or IL-1β and 
PolyIC. Co-stimulation with IL-1α or IL-1β and LPS induced an additive effect on GMCSF, IL-6 and 
IL-8 secretion in fibroblasts isolated from both tissues. Co-stimulation with IL-1α or IL-1β and HMGB1 
had no additional effect on GMCSF, IL-6 and IL-8 secretion compared to treatment with IL-1α or IL-1β 
alone. Treatment of fibroblasts with HMGB-1 and polyIC or LPS had little to no effect on GMCSF, IL-6 
and IL-8 secretion compared to treatment with polyIC or LPS alone (Fig. 5, Supplementary Figure 6).
IL-1α and IL-1β induce a potent pro-inflammatory phenotype in fibroblasts isolated from both tis-
sues. PolyIC and LPS similarly induce a pro-inflammatory phenotype but the magnitude of the response 
is reduced. PolyIC has a strong synergistic effect with IL-1α and IL-1β on GM-CSF secretion from 
fibroblasts isolated from both tissues.
Discussion
TKA alleviates pain and restores function in patients who have degenerative knee joint diseases. Although 
a highly successful operation, some 3–10% of individuals go on develop fibrosis in the form of arthrofi-
brosis post-surgery. Arthrofibrosis following TKA is described as a fibrosing pathology of the synovial 
membrane15 and infra-patellar fat pad16 for which there is no recommended therapeutic intervention. 
However, a pilot clinical study by Brown et al.8 demonstrated a marked improvement in range of motion 
and pain in patients with arthrofibrosis suggesting an important role for IL-1R1 in the pathology. In this 
study we have shown that fibroblasts isolated from the infra-patellar fat pad and synovial membrane 
express high levels of IL-1R1 on the cell surface and are induced to adopt a highly inflammatory pheno-
type in response to stimulation with IL-1α and IL-1β . In contrast, TGF-β 1 induced an increase in fibrotic 
gene expression suggesting that these cells are plastic and can modulate their phenotype in response to 
changes in the microenvironment.
Our data is in agreement with previous studies in other tissues showing that IL-1α and IL-1β can 
drive an inflammatory phenotype in fibroblasts. For example a study by Boxman et al. has demonstrated 
that IL-1α released from activated keratinocytes induces an increase in IL-8 and IL-6 production in 
human dermal fibroblasts17. IL-1α has been shown to be a potent stimulator of GM-CSF, IL-6 and IL-8 
expression in fibroblasts isolated from histologically normal human duodenal biopsy tissues18. IL-1β has 
been demonstrated to stimulate the secretion of IL-6 and IL-8 in rheumatoid arthritis fibroblast like 
www.nature.com/scientificreports/
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synoviocytes19. Finally, previous work from our laboratory has shown that IL-1α released from damaged 
human lung epithelial cells induces a potent pro-inflammatory phenotype in human lung fibroblasts12.
There is also a significant body of work demonstrating that IL-1α , IL-1β and IL-1R1 are involved in 
inflammation and fibrosis in vivo. For example, IL-1R1 KO mice are protected from bleomycin induced 
lung fibrosis and nasal installation of recombinant murine IL-1β into C57Bl6 mice induced lung tissue 
remodelling comparable to bleomycin20. Furthermore, adenoviral induced transient overexpression of 
IL-1β in rat lungs was accompanied by local increase in proinflammatory cytokines and severe progres-
sive tissue fibrosis21. Liu et al. demonstrated that IL-1β plays a critical role in radiation induced skin 
Figure 4. Stimulation of infra-patellar fat pad derived fibroblasts with IL-1α and IL-1β increases 
secretion of inflammatory mediators. Fibroblasts isolated from infra-patellar fat pad (n = 5) were 
stimulated with increasing doses of LPS (0.1–20 μ g/ml), HMGB1 (1–200 ng/ml), PolyIC (0.1–20 μ g/ml), 
IL-1α and IL-1β (both 25–1000 pg/ml) for 24 hours and the secreted levels of GM-CSF (a), IL-6 (b) and 
IL-8 (c) determined by ELISA. All three molecules demonstrated a dose dependant increase in secretion 
in response to PolyIC, IL-1α and IL-1β . LPS induced maximum release of all three molecules at the lowest 
concentration used (0.1 μ g/ml) with higher concentrations having no additional effect. The cells showed no 
significant response to HMGB-1. Data is presented as mean ± standard error of the mean with statistical 
significance compared to control indicated by; *p < 0.05, **p < 0.01 and ***p < 0.001.
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fibrosis22. Stimulation of human proximal tubule cells isolated from histologically normal segments of 
renal cortex with IL-1β enhanced fibronectin production and promoted α -smooth muscle actin expres-
sion23 and IL-1R1 KO & IL-1β KO mice are protected from injury and collagen deposition in the unilat-
eral ureteric obstruction model of kidney fibrosis24. Finally, IL-1R1 KO mice also exhibited ameliorated 
liver damage and reduced fibrogenesis in response to treatment with thioacetamide25. However, there are 
currently no studies that we are aware of that have selectively depleted IL-1R1 on fibroblasts to confirm 
a direct involvement of the receptor expressed on fibroblasts in fibrosis.
Figure 5. PolyIC and LPS increase IL-1α/IL-1β induced secretion of inflammatory mediators in 
infra-patellar fat pad derived fibroblasts. Fibroblasts isolated from infra-patellar fat pads (n = 5) were 
stimulated with IL-1α , IL-1β (both 500 pg/ml), LPS, PolyIC (both 5 μ g/ml) or HMGB-1 (50 ng/ml) alone or 
in combination for 24 hours and the secretion of IL-8, IL-6 and GM-CSF quantified by ELISA. (a,b) IL-1α 
and IL-1β induced secretion of GMCSF was accentuated by PolyIC. In contrast, Poly IC induced only an 
additive effect on IL-1α and IL-1β induced secretion of IL-6 and IL-8. LPS induced an additive effect on 
IL-1α and IL-1β induced secretion of GMCSF, IL-6 and IL-8 while HMGB1 had no effect. (c) Co-treatment 
with HMGB-1 and LPS or PolyIC was not significantly different to treatment with LPS or PolyIC alone. Data 
presented as mean ± standard error of the mean.
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Our data shows that fibroblasts isolated from the synovial membrane and infrapatellar fat pad express 
similar levels of IL-1R1 on the cell surface and that the IL-1α /IL-1β induced inflammatory response is 
of similar magnitude. It is therefore likely that the induction of an inflammatory response in fibroblast 
in vivo is regulated by the availability/expression of IL-1α and IL-1β in the tissue and that Anakinra can 
exert an inhibitory effect on IL-1R1 expressed on fibroblasts present in both tissues in vivo. However 
further research is required to determine the in vivo tissue/tissues targeted by Anakinra in patients with 
arthrofibrosis to help improve our understanding of the pathology and how it can be treated.
In summary, there are currently no approved therapeutic interventions available for the treatment of 
arthrofibrosis excluding a TKA revision surgery. Revision surgeries put patients at risk of complications 
from anaesthesia, infection and pain amongst others. Revision surgery also comes at a great cost includ-
ing surgeon’s time, theatre use, theatre staff and equipment. A pilot study has demonstrated a beneficial 
effect of treatment with Anakinra in patients with arthrofibrosis. In this study we propose a potential 
mechanism for the reported beneficial impact of Anakinra on patients with arthrofibrosis, via inhibition 
of IL-1R1 on fibroblasts.
Methods
Patient recruitment and ethics. This study was performed in accordance with approval from the 
Newcastle and North Tyneside Local Regional Ethics Committee and informed written consent from all 
study patients (12/NE/0395).
Tissue processing and cell isolation. Infra-patellar fat pad and synovial membrane were acquired 
from patients (n = 6) undergoing primary TKA at the Freeman Hospital Newcastle upon Tyne NHS 
Foundation Trust. Tissues were homogenized and digested in 10 ml of supplement free Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma) containing 100 cdg units/ml of collagenase (Sigma). Digested 
tissue was passed through a 100 μ m filter and the collagenase neutralized with complete DMEM (10% 
FCS, 100 μ g/ml Streptomycin, 100 U/ml penicillin, 1% L-glutamate and 0.5 μ g/ml amphotericin B). Cells 
were pelleted and re-suspended in complete DMEM before transferring into T-75 flasks. Cells were 
cultured at 37 °C and 5% CO2 until > 90% confluent. Cells were cryopreserved (DMSO freezing media, 
Sigma) at P0 or passaged and cryopreserved at P1. Cells were reanimated and used between P3 and P5 
for experiments.
PBEC from stable lung transplant recipients were isolated as previously described26. Human bronchial 
epithelial cell line (16HBE14o−) were cultured as described previously27.
Cell treatments. Cells were seeded at 7 × 103 cells/cm2 and treated for 24 hours with increasing doses 
of recombinant human HMGB-1 (1–200 ng/ml), IL-1α (25–1000 pg/ml), IL-1β (25–1000 pg/ml) (all 
R&D), LPS (0.1–20 μ g/ml) and PolyIC (0.1–20 μ g/ml) (both Sigma) or for 24 hours with LPS (5 μ g/ml), 
PolyIC (5 μ g/ml), HMGB-1 (50 ng/ml), IL-1α (500 pg/ml) and IL-1β (500 pg/ml) alone or in combina-
tion. Cell culture supernatants were harvested for ELISA. For PCR, cells were seeded at 7 × 103 cells/cm2  
and treated for 48 hours with TGF-β 1 (3 ng/ml).
Immunocytochemistry. Cells (1 × 104 cells/cm2) were seeded onto coverslips for 24 hours and fixed 
in 4% paraformaldehyde. Subsequently cells were washed and quenched with 100 mM glycine before 
permeabilisation using 0.1% Triton X-100 and blocking with 5% bovine serum albumin (BSA). Primary 
antibodies (α -SMA (Ab5694, Abcam), β -tubulin (T4026, Sigma), collagen I (C2456, Sigma), cytokine 17 
(Ab53707, Abcam), E-cadherin (610181, BD Bioscience), fibronectin (F3648, Sigma), vimentin (Ab92547, 
Abcam & M7020, Dako) and ZO-1 (33–9100, Zymed)) were added and incubated overnight at 4° C in 
5% BSA. Cells were washed with 0.2% tween-20 in PBS and then incubated with secondary antibodies 
(anti-rabbit TRITC (T6778, Sigma) and anti-mouse Alexafluor 488 (A11001, Molecular Probes)) for 
60 mins in 5% BSA. Cover slips were washed and mounted in mounting media containing DAPI (Vectra 
Shield). Images acquired using a Leica TCS SP2 UV confocal microscope.
Western Blot. Whole cell lysates were prepared by sonication of cells. Protein concentration of 
samples were determined by BCA protein assay (Thermo Scientific) as per manufacturer’s instruc-
tions. Samples (5 or 10 μ g) were separated under denaturing conditions on a NuPage 4–12% Bis-Tris 
gels (Invitrogen). Gels were then transferred onto Hybond-P polyvinylidene fluoride (PVDF) mem-
branes, blocked and incubated with primary antibody (β -actin (A2228, Sigma), E-cadherin (610181, 
BD Bioscience), fibronectin (F3648, Sigma), vimentin (Ab92547, Abcam), TLR3 (12–9039, eBioscience), 
TLR4 (51–9917–73, eBioscience) and IL-1R1 (AF269, R&D). Membranes were washed and incubated 
with HRP conjugated secondary antibodies (Ab6820 & Ab6721, Abcam) before being washed and visual-
ised using SuperSignal Pico Chemiluminescent Substrate (Thermo-Scientific) and X-ray film. Full blots 
for all antibodies are shown in supplementary Figure 7.
RNA Isolation. RNA was isolated using NucleoSpin® RNA II kit (MACHEREY-NAGEL) as per man-
ufacturer’s instructions. cDNA was generated using the AffinityScript™ Multiple Temperature RT kit 
(Alignment Technologies) as per manufactures instructions.
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qRT-PCR. qRT-PCR was used to investigate gene expression of TLR 1–10, RIG, RAGE, IL-1R1, 
α -SMA, collagen I/III and fibronectin (Table  1). Master mix was generated by aliquoting sybr green 
(Sigma-Aldrich), RNase-free H2O and the appropriate primer to duplicate wells on a 96 well PCR plate 
(Applied Biosystems). cDNA samples were diluted to 5ng/ml before adding to the plate. Plates were 
run as per protocol (7500 Fast RT-PCR, Applied Biosystems). Cycle threshold values were averaged and 
relative gene expression calculated against GAPDH.
Flow cytometry. Cells were preincubated in LIVE/DEAD (L34955, Life Technologies) to determine 
cell viability followed by incubation with specific mAbs (TLR3 (eBioscience 12–9039), TLR4 (eBioscience 
51–9917–73) and IL-1R1 (R&D AF269)) diluted in PBS/1% BSA. After staining, cells were washed and 
resuspended in PBS/1% BSA for analysis. Isotype controls (IC108A, R&D & 12–4714–71, eBioscience) 
were included as negative controls. Data was acquired on a BD FACSCanto II and analyzed using FlowJo 
software.
ELISA. IL-6, IL-8, GM-CSF levels in cell culture media was measured using ELISA DuoSet kit (R&D 
Systems) as per manufacturer’s protocols. Level of detection – GMCSF – 15.6 pg/ml, IL-8–31.2 pg/ml & 
IL-6–9.4 pg/ml.
Statistical analysis. Results are presented as mean ± standard error of the mean (SEM). Differences 
between treatment groups were analysed using students t-test (Graphpad Prism 6 statistical software). 
Probability (P) values of < 0.05 were regarded as significant.
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